Hosted on MSN20h
Omvoh Approved for Crohn's; Fitbit Predicts IBD Flares; H. Pylori and Gastric CancerThe FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...
Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...
Marks the Third Year Since the Launch of the First US Biosimilar Market Report; INCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today released it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback